|1.||Wilson, William R: 3 articles (05/2013 - 10/2009)|
|2.||Guise, Christopher P: 2 articles (02/2014 - 05/2013)|
|3.||Patterson, Adam V: 2 articles (02/2014 - 10/2009)|
|4.||Clin, B: 1 article (08/2015)|
|5.||Marquignon, M-F: 1 article (08/2015)|
|6.||Letourneux, M: 1 article (08/2015)|
|7.||Boulanger, M: 1 article (08/2015)|
|8.||Bienvenu, B: 1 article (08/2015)|
|9.||Silva, Bruno Leonardo: 1 article (01/2015)|
|10.||de Oliveira, Mônica Cristina: 1 article (01/2015)|
|2.||Acute Lung Injury
01/01/2015 - "Twenty-seven nitrated and non-nitrated compounds have been synthesized and tested for their growth inhibitory activity on three human cancer cells lines. "
09/01/1985 - "A review of the literature on radiosensitization reveals that at least some of the non-nitro compounds, such as metabolic inhibitors and membrane-active drugs, could be considered as potentially valuable radiosensitizers for possible use in future cancer radiotherapy."
05/01/1975 - "More than 200 nitro compounds, most of them nitroaniline derivatives substituted with one or more radicals having a basic reaction, were prepared and investigated as to their therapeutic activity against bacteria, fungi, protozoa, helminths, viruses and tumors. "
06/01/1947 - "Chemotherapy investigations in cancer; with reference to the influence of certain organic dibasic acids, diamino compounds and nitro compounds on tumors in mice."
01/01/1997 - "These prodrug designs also have potential for releasing effectors other than nitrogen mustards, which opens up many possibilities for use of nitro compounds as tumor-selective prodrugs."
01/01/2013 - "In contrast, Class II HAP (such as the nitro compounds PR-104A or TH-302) are maximally activated only under extreme hypoxia, but their active metabolites (effectors) diffuse to cells at intermediate O2 and thus also eliminate moderately hypoxic cells. "
10/01/2009 - "Of three alkylating subunits investigated, the chloromethylbenzindoline (CBI) structure provided the most favorable prodrug properties: aerobic cytotoxic potency of the amines was approximately 90- to 3,000-fold higher than the corresponding nitro compounds, and the nitro compounds showed air/anoxia potency differentials of up to 300-fold. "
11/01/1982 - "[Effect of exogenous amino acids on myocardial contraction and metabolism of nitro-compounds in the myocardium during anoxia]."
05/15/2013 - "One-electron reductases that reduce nitro compounds in hypoxic human tumour cells are poorly characterized, but are important for targeting hypoxia with nitroaromatic prodrugs. "
01/01/1995 - "Radicals from one-electron reduction of nitro compounds, aromatic N-oxides and quinones: the kinetic basis for hypoxia-selective, bioreductive drugs."
05/01/2014 - "[Analysis of the literature on acute aromatic amino or nitro-compounds poisoning]."
04/26/1969 - "[On the chronic poisoning by nitrated compounds in the workers of explosive factories]."
05/29/1952 - "[Poisoning by aromatic amino- and nitro compounds]."
01/01/1960 - "[Methemoglobinemia caused by poisoning with aromatic nitro compounds]."
10/01/1974 - "[Role of adrenal cortical dysfunction ingenesis of clinical syndromes of poisoning by certain industrial poisons (aromatic nitro compounds, lead)]."
|1.||Peroxynitrous Acid (Peroxynitrite)
|1.||Drug Therapy (Chemotherapy)